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1. INTRODUCTION {#dom13143-sec-0001}
===============

The prevalence rates of obesity and type 2 diabetes have increased concomitantly in the USA during the last 30 years.[1](#dom13143-bib-0001){ref-type="ref"}, [2](#dom13143-bib-0002){ref-type="ref"}, [3](#dom13143-bib-0003){ref-type="ref"} Obesity, and in particular abdominal obesity, is also a major risk factor for type 2 diabetes,[4](#dom13143-bib-0004){ref-type="ref"}, [5](#dom13143-bib-0005){ref-type="ref"} suggesting that the increase in the prevalence of obesity has contributed, at least in part, to the increase in the prevalence of type 2 diabetes. The aims of the present study were to assess the trends in the prevalence of type 2 diabetes and abdominal obesity in the USA from 1999 to 2014, and to examine whether the trends in the prevalence of type 2 diabetes differ between abdominally obese and non‐obese individuals. Our hypothesis was that the association between obesity and type 2 diabetes was contributing to growing health disparities and could justify more focused primary prevention programmes, for instance, targeting US residents presenting with obesity.

2. METHODS {#dom13143-sec-0002}
==========

The National Health and Nutrition Examination Survey (NHANES) is a programme of studies designed to assess the health and nutritional status of adults and children in the USA. It has been conducted by the Centers for Disease Control and Prevention since the early 1960s. Beginning in 1999, every 2 years, NHANES examined a nationally representative sample of \~10 000 individuals from the resident, civilian, non‐institutionalized US population. The survey consisted of an interview conducted in the home, followed the next day by a standardized health examination in specially equipped mobile examination centres that included a physical examination administered by trained medical personnel as well as laboratory tests.

Whole‐blood specimens were drawn from all participants aged ≥12 years, then processed and stored under appropriate refrigerated (5°C) conditions. Specimens collected in 2013 to 2014 were shipped to the University of Missouri‐Columbia for measurement of glycated haemoglobin (HbA1c) using the Tosoh G8 Glycohemoglobin Analyzer (Tosoh Medics, Inc., San Francisco, California). There have been changes in the equipment and location since 1999; however, NHANES recommends using the original data, without a cross‐over study regression equation, for all analyses, including trend analyses. Abdominal circumference was measured with a tape drawn just above the uppermost lateral border of the right and left ilia. More information about data collection methods as well as the complex sampling design are available elsewhere (<http://www.cdc.gov/nchs/nhanes.htm>).

The population eligible for the present analysis consisted of individuals aged ≥20 years enrolled in any of the eight 2‐year surveys conducted from 1999/2000 to 2013/2014. NHANES 2013/2014 was the latest survey with publicly available data at the date of download (February 27, 2017). Pregnant women were excluded.

Type 2 diabetes was identified when the NHANES participant answered yes to the question: "Other than during pregnancy, have you ever been told by a doctor or another health professional that you have diabetes or sugar diabetes?", or when HbA1c was ≥6.5%. Participants diagnosed with diabetes at age \< 30 years who required insulin therapy were assumed to have type 1 diabetes and were excluded from the type 2 diabetes population. Abdominal obesity was defined as waist circumference \> 102 cm for men and \>88 cm for women.[4](#dom13143-bib-0004){ref-type="ref"} For sensitivity analyses, overweight and obesity were also defined as body mass index (BMI) ≥ 25 and 30 kg/m^2^, respectively.

Other variables retained for analysis were sex, age in years, grouped as 20 to 44, 45 to 64, and ≥65 years, and race/ethnicity (non‐Hispanic white, non‐Hispanic black, Hispanic and other).

Statistical procedures were conducted with SAS version 9.4 software (SAS Institute, Inc., Cary, North Carolina), with sampling weights provided by NHANES, accounting for the stratified, clustered sample design. Estimates were standardized according to the distributions of the non‐institutionalized population of the USA by age group, sex and race/ethnicity on January 1, 2014, as per estimations from the US Census Bureau. Time trends for the prevalence of type 2 diabetes and obesity were assessed using logistic regression models, and for the mean waist circumference using linear regression models, with the year of the survey entered as a continuous variable, from 0 for NHANES 1999/2000 to 14 for NHANES 2013/2014. Interactions with age were estimated in the full dataset, with age group considered as an ordinal variable. Sensitivity analyses were conducted to assess secular trends in the prevalence of abdominal obesity and type 2 diabetes by race/ethnicity.

NHANES was approved by the National Center for Health Statistics Research Ethics Review Board. All adult participants provided written informed consent.

3. RESULTS {#dom13143-sec-0003}
==========

The size of the resident, non‐institutionalized population of the USA ([Table S1](#dom13143-supitem-0001){ref-type="supplementary-material"}) increased from 272.2 to 311.2 million from January 1, 2000 to January 1, 2014, with a population that has become ethnically more diverse: of 230.6 million non‐institutionalized US residents aged ≥20 years on January 1, 2014, 151.9 million (66%) were non‐Hispanic white, 26.7 million (12%) were non‐Hispanic black, 34.5 million (15%) were Hispanic, and 17.5 million (7%) were from another race or ethnicity. The size of the sample screened for NHANES increased from 12 160 in 1999/2000 to 14 332 in 2013/2014, with a response rate (NHANES participants over screened sample) that decreased from 82% in 1999/2000 to 71% in 2013/2014, but remained consistently higher than 70%. After exclusion of pregnant women and individuals aged ≤20 years, about one‐half of the NHANES participants were eligible for analysis. More than 90% of the eligible participants (38 234/42 377) were retained for analysis. The most frequent reason for exclusion was missing HbA1c data. The frequency of missing data decreased continuously from 14% in 1999/2000 to 7% in 2013/2014, and the proportion of NHANES participants with missing HbA1c was not significantly associated with a prior diagnosis of diabetes ([Table S2](#dom13143-supitem-0001){ref-type="supplementary-material"}).

The prevalence of type 2 diabetes and abdominal obesity (Table [1](#dom13143-tbl-0001){ref-type="table-wrap"}) increased significantly between 1999/2000 and 2013/2014 from 8.8% (95% confidence interval \[CI\] 7.2‐10.4) to 11.7% (95% CI 10.9‐12.6) for type 2 diabetes, and from 47.4% (95% CI 42.6‐52.2) to 57.2% (95% CI 55.9‐58.5) for abdominal obesity (*P* \< .001 for both), after standardization to the age, sex, and race/ethnicity distributions in 2014. The prevalence of diabetes increased significantly among US residents aged ≥45 years, but no significant time trend was observed among individuals aged 20 to 44 years, while the prevalence of abdominal obesity increased in all age groups.

###### 

Prevalence of type 2 diabetes and abdominal obesity from 1999/2000 to 2013/2014, stratified by age group

                                Prevalence of type 2 diabetes and abdominal obesity, % (95% CI)                                                                                                                                                                                         
  ----------------------------- ----------------------------------------------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ----------------------
  Type 2 diabetes               3959                                                              4492                      4316                      4189                      5300                      5684                      4966                      5328                      Mean change per year
  20--44 years                  2.3(1.4;3.1)n = 1614                                              3.4(2.0;4.8)n = 1892      2.8(1.8;3.8)n = 1746      3.2(2.1;4.4)n = 1794      2.6(1.8;3.4)n = 2080      2.5(1.7;3.3)n = 2381      3.5(2.5;4.5)n = 2141      3.3(2.6;4.0)n = 2265      0.04(−0.03;0.10)
  45--64 years                  11.8(9.5;14.2)1224                                                11.8(9.0;14.7)n = 1417    13.2(11.0;15.3)n = 1262   13.0(10.7;15.2)n = 1329   14.3(11.7;16.9)n = 1845   13.3(11.4;15.2)n = 1925   14.3(11.8;16.8)n = 1733   15.5(13.1;17.8)n = 1846   0.24(0.06;0.41)
  ≥65 years                     18.4(14.2;22.6)n = 1121                                           18.5(15.9;21.1)n = 1183   22.5(18.3;26.6)n = 1308   20.9(18.3;23.4)n = 1066   24.7(20.6;28.8)n = 1375   25.7(22.6;28.7)n = 1378   22.4(19.5;25.3)n = 1092   24.6(22.2;27.0)n = 1217   0.46(0.23;0.69)
  **Total population**          8.8(7.2--10.4)                                                    9.3(7.8--10.8)            10.3(8.9--11.7)           10.1(8.8--11.4)           11.0(9.5--12.6)           10.8(9.8--11.8)           11.0(9.5--12.5)           11.7(10.9--12.6)          0.19(0.09--0.28)
  Abdominal obesity             3847                                                              4296                      4110                      4014                      5062                      5421                      4709                      5059                      Mean change per year
  20--44 years                  36.5(32.0;41.1)n = 1582                                           36.6(34.5;38.7)n = 1835   41.8(38.3;45.3)n = 1684   42.2(37.4;46.9)n = 1741   42.2(38.4;45.9)n = 2017   42.3(38.4;46.3)n = 2298   43.8(39.1;48.5)n = 2064   48.1(45.8;50.4)n = 2193   0.71(0.45;0.97)
  45--64 years                  54.5(48.3;60.7)n = 1200                                           56.6(53.1;60.1)n = 1378   61.0(57.6;64.4)n = 1225   58.9(54.5;63.4)n = 1294   60.5(56.6;64.4)n = 1778   61.5(57.7;65.2)n = 1856   63.4(58.8;68.0)n = 1661   62.3(59.7;64.9)n = 1768   0.55(0.23;0.86)
  ≥65 years                     60.0(55.1;64.8)n = 1065                                           62.5(59.3;65.7)n = 1083   67.0(62.9;71.1)n = 1201   66.4(62.5;70.3)n = 979    66.5(62.1;70.8)n = 1267   68.0(65.2;70.9)n = 1267   68.3(63.0;73.6)n = 984    69.9(64.7;75.1)n = 1098   0.61(0.28;0.94)
  **Total population**          47.4(42.6;52.2)                                                   48.6(46.3;50.9)           53.4(50.6;56.2)           52.7(49.0;56.3)           53.2(50.3;56.1)           54.0(51.0;57.0)           55.3(51.3;59.4)           57.2(55.9;58.5)           0.62(0.38;0.86)
  Missing waist circumference   112                                                               196                       206                       175                       238                       263                       257                       269                       

The prevalence of diabetes remained stable among non‐obese individuals, with a mean annual change from 1999/2000 to 2013/2014 of 0.00% (95% CI --0.09 to 0.09; *P* = .80 \[Table [2](#dom13143-tbl-0002){ref-type="table-wrap"}\]), whereas it increased significantly among abdominally obese individuals, with an annual percentage change of 0.22% (95% CI 0.08‐0.36; *P* \< .01). This trend in abdominally obese individuals widened with age, as the annual percentage change increased from 0.05% (95% CI --0.09 to 0.20) in individuals aged 20 to 44 years to 0.31% (95% CI 0.09‐0.54) in those aged 45 to 64 years and 0.48% (95% CI 0.18‐0.78) in those aged ≥65 years (*P* value for the interaction term \<.01). These diverging trends resulted in larger differences in the prevalence of type 2 diabetes as a function of age and abdominal obesity in 2013/2014 compared with 1999/2000, with up to 30% of the abdominally obese individuals aged ≥65 years having type 2 diabetes (30.3%; 95% CI 27.4‐33.3) in 2013/2014 vs 23.8% (95% CI 18.4‐29.2) in 1999/2000. The overall number of adult US residents with abdominal obesity and type 2 diabetes increased from 11.4 million in 1999/2000 to 22.9 million in 2013/2014.

###### 

Prevalence of type 2 diabetes in the abdominally obese and non‐obese populations, stratified by age group

                                 Prevalence, % (95% CI)                                                                                                                                                                                              
  ------------------------------ ------------------------- ------------------------- ------------------------- ------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ----------------------
  Abdominally obese population   1935                      2180                      2240                      2156                      2866                       3068                       2526                       2854                       Mean change per year
  20--44 years                   4.7(2.6--6.8)n = 615      6.1(3.5--8.7)n = 705      5.5(3.2--7.8)n = 699      6.3(3.7--8.8)n = 751      5.0(3.4--6.5)n = 900       4.6(2.8--6.4)n = 1033      7.0(5.1--8.8)n = 895       5.8(4.2--7.5)n = 1044      0.05(−0.09 to 0.20)
  45--64 years                   16.0(13.0--19.0)n = 693   14.1(11.0--17.2)n = 820   17.4(14.5--20.4)n = 769   16.9(13.5--20.3)n = 784   20.2(17.1--23.4)n = 1120   18.0(15.4--20.5)n = 1179   18.1(14.1--22.0)n = 1014   20.1(17.2--23.0)n = 1066   0.31(0.09--0.54)
  ≥65 years                      23.8(18.4--29.2)n = 627   22.7(19.9--25.5)n = 655   26.3(19.6--32.9)n = 772   25.5(21.8--29.2)n = 621   28.2(24.0--32.4)n = 846    30.0(26.0--34.1)n = 856    27.0(23.4--30.6)n = 617    30.3(27.4--33.3)n = 744    0.48(0.18--0.78)
  **Total population**           13.9(11.6--16.2)          13.4(11.5--15.3)          15.2(13.1--17.3)          15.0(12.9--17.2)          16.5(14.4--18.6)           16.0(14.6--17.4)           16.1(13.5--18.6)           16.9(15.6--18.2)           0.22(0.08--0.36)
  Non‐obese population           1912                      2116                      1870                      1858                      2196                       2353                       2183                       2205                       Mean change per year
  20--44 years                   0.8(0.1--1.4)n = 967      1.8(0.9--2.6)n = 1130     0.8(0.4--1.3)n = 985      1.0(0.3--1.8)n = 990      0.9(0.4--1.5)n = 1117      0.8(0.3--1.2)n = 1265      0.6(0.2--1.1)n = 1169      0.7(0.3--1.2)n = 1149      −0.04(−0.8 to 0.1)
  45--64 years                   6.2(3.3--9.2)n = 507      7.6(4.2--11.1)n = 558     5.7(2.5--8.9)n = 456      6.8(3.2--10.4)n = 510     5.0(3.0--7.0)n = 658       4.6(2.3--6.9)n = 677       7.2(4.7--9.7)n = 647       6.3(4.5--8.2)n = 702       −0.04(−0.23 to 0.14)
  ≥65 years                      9.1(5.5--12.6)n = 438     12.5(6.3--18.7)n = 428    13.9(10.9--16.9)n = 429   9.7(4.6--14.7)n = 358     16.4(10.7--22.0)n = 421    15.9(11.8--20.0)n = 411    12.1(7.0--17.2)n = 367     12.5(8.9--16.1)n = 354     0.23(−0.08 to 0.54)
  **Total population**           3.7(2.2--5.1)             5.0(3.3--6.7)             4.0(3.0--5.1)             4.0(3.0--5.0)             4.2(3.1--5.3)              3.9(2.7--5.1)              4.1(3.0--5.2)              4.0(3.2--4.8)              0.00(−0.09 to 0.09)

We observed the same association between type 2 diabetes and obesity measured by BMI, with the prevalence of type 2 diabetes increasing significantly only in individuals aged ≥45 years with a BMI ≥30 kg/m^2^ ([Table S3](#dom13143-supitem-0001){ref-type="supplementary-material"}). The severity of abdominal obesity also worsened over time, as demonstrated by a significant increase in the mean waist circumference in abdominally obese men and women from 1999/2000 to 2013/2014 ([Table S4](#dom13143-supitem-0001){ref-type="supplementary-material"}).

Sensitivity analyses by race/ethnicity showed similar percent increases in the prevalence of type 2 diabetes, with mean annual changes of 0.19% (95% CI 0.09‐0.30), 0.27% (95% CI 0.09‐0.46) and 0.19% (0.09‐0.29) among non‐Hispanic white, non‐Hispanic black and Hispanic people, respectively. Consistent trends were also observed for the prevalence of abdominal obesity, with mean annual changes of 0.59% (95% CI 0.29‐0.88), 0.74% (95% CI 0.48‐1.00) and 1.10% (95% CI 0.78‐1.42) among non‐Hispanic white, non‐Hispanic black and Hispanic people, respectively.

4. DISCUSSION {#dom13143-sec-0004}
=============

This study, in which the most recent data from NHANES, including the 2013/2014 survey, were analysed, confirms that the prevalence of both type 2 diabetes and obesity have continued to increase since 1999/2000. The prevalence of abdominal obesity increased in all age groups: 20 to 44, 45 to 64, and ≥65 years; however, the increase in the prevalence of type 2 diabetes was limited to individuals with abdominal obesity, and more specifically to individuals aged ≥45 years with abdominal obesity, with no significant change in prevalence in the non‐obese group and in individuals aged \<45 years.

The increase in the prevalence of abdominal obesity and type 2 diabetes among the abdominally obese, combined with the aging of the population, resulted in a doubling of the number of US residents aged ≥20 years with abdominal obesity and type 2 diabetes from 1999/2000 to 2013/2014.

The present study analysed data from NHANES, which is a series of cross‐sectional surveys of large representative samples of the resident non‐institutionalized adult population of the USA. These surveys have been conducted consistently every 2 years since 1999 and included an interview and physical examination as well as laboratory tests that make possible a comprehensive assessment of each participant\'s health status.

Our operational definition for type 2 diabetes, previous diagnosis by a healthcare practitioner or HbA1c ≥6.5%, differs from other publications that analysed NHANES data, and also took into account a fasting blood glucose \>125 mg/dL and a 2‐hour post‐load plasma glucose measurement ≥200 mg/dL.[1](#dom13143-bib-0001){ref-type="ref"}, [6](#dom13143-bib-0006){ref-type="ref"}, [7](#dom13143-bib-0007){ref-type="ref"} Accordingly, our prevalence estimates for diabetes by age group are slightly lower than those recently published using data from NHANES 2011/2012 and 2013/2014.[1](#dom13143-bib-0001){ref-type="ref"}, [7](#dom13143-bib-0007){ref-type="ref"} We retained this definition because fasting blood glucose was documented in only 44% of the participants aged ≥20 years in NHANES 2013/2014 (2574 of 5769) while HbA1c was documented in \>85% of the participants in each NHANES survey, with the proportion of missing data decreasing over time (7% in 2013/2014). The proportion of NHANES participants with missing HbA1c was also not significantly associated with a prior diagnosis of diabetes. In addition, HbA1c was determined from blood samples in a consistent manner throughout the present study period; therefore, we considered that an operational definition based on a previous diagnosis by a healthcare practitioner or HbA1c not only increased the power of the analysis vs a more complex definition that included fasting blood glucose, but was also unbiased across the different surveys.

We retained obesity as measured by waist circumference rather than by BMI because abdominal obesity has been described as a stronger independent predictor, not only of cardiovascular events[8](#dom13143-bib-0008){ref-type="ref"} and mortality,[9](#dom13143-bib-0009){ref-type="ref"} but also of type 2 diabetes[5](#dom13143-bib-0005){ref-type="ref"}, [10](#dom13143-bib-0010){ref-type="ref"}; however, we observed the same association between type 2 diabetes and obesity measured by BMI, with the prevalence of type 2 diabetes increasing significantly only in individuals aged ≥45 years with a BMI ≥30 kg/m^2^. More specific waist circumference cut‐off points for the definition of abdominal obesity have been recently suggested as a function of race/ethnicity with lower thresholds among the South‐Asian, Chinese and Japanese racial/ethnic groups[11](#dom13143-bib-0011){ref-type="ref"}; however, we retained cut‐off points independent of race/ethnicity, in particular, because NHANES did not identify participants in the Asian ethnic groups until 2011/2012.

As the data were collected from cross‐sectional surveys in independent populations sampled every 2 years, we cannot interpret our findings as direct evidence of a causal relationship between obesity and type 2 diabetes. Nevertheless, the results are consistent with those from longitudinal studies that have pointed to obesity and, in particular, abdominal obesity, as a risk factor for type 2 diabetes.[5](#dom13143-bib-0005){ref-type="ref"}, [12](#dom13143-bib-0012){ref-type="ref"}, [13](#dom13143-bib-0013){ref-type="ref"} Furthermore, our finding that the increase in the prevalence of type 2 diabetes is restricted to individuals aged ≥45 years, while the increase in prevalence of abdominal obesity affects all age groups, is consistent with the hypothesis that diabetes may result from the cumulative burden of obesity over time. From this perspective, the continuous increase in the prevalence of abdominal obesity that is observed in all age groups, and, in particular, in individuals aged 20 to 44 years, is concerning because it suggests the prevalence of type 2 diabetes should keep increasing in the next few years.

There is a trend towards an increase in the prevalence of type 2 diabetes in non‐obese individuals aged ≥65 years, with a mean increase per year of 0.23% (95% CI --0.08 to 0.54). This trend remains non‐significant (*P* = .15), perhaps because our study was underpowered, although a total of 3206 non‐obese individuals aged ≥65 years were retained for analysis.

The absence of any significant increase in the prevalence of type 2 diabetes in all participants aged 20 to 44 years also needs to be interpreted with caution as other studies have found a significant increase among young adults, not only in type 1 but also in type 2 diabetes.[14](#dom13143-bib-0014){ref-type="ref"}, [15](#dom13143-bib-0015){ref-type="ref"}

The stable prevalence of type 2 diabetes among individuals without abdominal obesity suggests minimal exposure to changing lifestyle risk factors among this group. Conversely, the increasing prevalence of type 2 diabetes in the obese population can be partly explained by more severe obesity over time, as demonstrated by an increase in the mean waist circumference in abdominally obese men and women between 1999/2000 and 2013/2014. However, other factors may have played a role, such as the development of abdominal obesity at an earlier age, as demonstrated by the increase in the prevalence of abdominal obesity among those aged 20 to 44 years, or other factors associated with obesity and diabetes such as dyslipidemia, hypertension, chronic inflammation, diet, physical exercise, and smoking status, which were not analysed in this study.

Growing disparities in the risk of type 2 diabetes have been observed not only as a function of abdominal obesity and age but also geographically, with widening differences in the prevalence of diabetes among US counties from 2004 and 2012.[16](#dom13143-bib-0016){ref-type="ref"} These disparities highlight the cumulative effect of risk factors in fragile populations and reinforce the rationale for focused primary prevention programmes.

In conclusion, the present findings highlight the critical importance of abdominal obesity, both as a key contributor to the continuing epidemic of type 2 diabetes in the USA, and as a high‐priority target for potential public health interventions. The burden of type 2 diabetes can be controlled, in part, by better management of its complications. Although some progress has been made in this direction,[17](#dom13143-bib-0017){ref-type="ref"} these results are achieved at a high financial cost. The burden of type 2 diabetes could also be controlled by primary prevention efforts and public health interventions that target modifiable risk factors: this study supports the prioritization of these efforts in the population with abdominal obesity.
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